GE HealthCare

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated
solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while
simplifying the patient’s journey across the care pathway.

Role of institution in the project

GE HealthCare will participate in WP 5, 6, 7 and 8 and will deploy use-cases of mass annotation to support the efficient creation of high-value, high-quality, interoperable and reusable datasets for clinical research and machine-learning, in view of creating a proper value stream for the reuse of healthcare imaging data compliant with EU regulations.

Baptiste Perrin

I joined GE in 2005 after a first experience at THALES as a software and hardware engineer in real time embedded processing for defense industry. Today, my responsibilities cover engineering activities around artificial intelligence (AI), oncology and partnership. I'm in touch with the French ecosystem with a focus on Advanced Visualization (2D, 3D or 4D). At GE, I started with the management of installed base on critical real time components inside interventional business. I then moved to pre-market activities and I lead different engineering teams (hardware and software) on different projects like DISCOVERY IGS. I then chose the software organization AW which offers software imaging solutions around CT, MR, PET modalities. Since 2015, I changed the V&V methodologies and aligned it with Agile, promoting strong relationship between the development and the test. I regrouped the oncological expertise in France and created the oncological team. The team contributed to deliver PROView (MR prostate), HVCAR (CT Hepatic) including AI, PETVCAR (MICT full boday), BoneVCAR. I initiated advanced project on artificial intelligence and started interactions with academics and startups. Looking backward, I would say that my main areas of interest are : Driving people, Delivering product Innovations and releasing, sustaining product on the market.

Henri Souchay

Henri Souchay has a PhD of Physics and Engineering Degree from Ecole Centrale Paris. The privilege of experience brought him to realize that not only the answers are important. What is key on our complex industry is to ask the right questions, because what KILLS your product/project is not what you KNOW you don't know, ie the questions you are able to ask, but what you DON'T KNOW that you don't know (and often, don't want to). The era of precision medicine demands collaborative research and innovations. Startups are able to explore rapidly and adapt to field needs, while larger companies have the experience of the rigor of traditional healthcare markets and regulation. While newer technologies are generating their own regulatory environment, he sees navigating these with our value-creating partners as the future for any high-quality, compliant and patient-centric care solution system -- both as a citizen-patient and an industrial economic player. He's honored to participate to the discussions within the French Strategic Committee working groups on valorization of healthcare data since 2019, and IHI since 2022.

Naïm Jalal

Naïm Jalal is a Technical Project Manager at GE HealthCare, working at the intersection of artificial intelligence and clinical innovation. He holds a PhD in computational modeling and biomechanics and is an engineer from INSA Lyon. At GE HealthCare, Naïm has been involved in launching and coordinating collaborative projects such as AI DReAM and eCAN RHU, supporting their early-stage structuring and operational follow-up. Before joining GE HealthCare, Naïm served as CTO at Caerus Medical, a health tech start-up, where he led the development of AI-driven solutions and helped shape the company’s technological roadmap. His experience has allowed him to consistently work across disciplines, leading multidisciplinary teams and aligning technical execution with clinical relevance. Naïm strives to translate complex scientific methods into practical, usable tools in the medical domain, ensuring project delivery across institutional and industrial stakeholders. His goal is to contribute to meaningful advancements in healthcare through innovative technology.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Find out more

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

WATCH THE RECORDING

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

Sign up for more information

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.

Participate